PF-05082566: Phase Ib data

Top-line data from 23 evaluable patients with advanced solid tumors in an open-label, U.S. Phase Ib trial showed that 0.45-5 mg/kg PF-2566 plus 2 mg/kg IV Keytruda pembrolizumab every 3 weeks led to ...